Oversubscribed new share issue prior to listing

The listing on Spotlight Stock Market has been preceded by a new share issue that provided Scandion Oncology approx. SEK 26 million before issue costs. The new share issue was subscribed to approx. SEK 104.7 million including subscription commitments of approx. SEK 18.5 million, corresponding to a total subscription ratio of approx. 402.7 percent. A total of 2,938 individuals subscribed for shares in the new share issue and Scandion Oncology received approx. 1,500 new shareholders.

Financial advisor

Sedermera Fondkommission was the financial advisor and issuing agency to Scandion Oncology in connection with the new share issue and the listing on Spotlight Stock Market. Nordnet Bank AB was acting as Selling Agent in the new share issue.

For additional information regarding the new share issue and listing, please contact:

Sedermera Fondkommission

Phone: +46 (0) 40-615 14 10

E-mail: info@sedermera.se

For additional information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells.